These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36082549)

  • 1. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study.
    Westerman ME; Bree KK; Msaouel P; Kukreja JB; Mantaring C; Rukundo I; Gonzalez MG; Gregg JR; Casteel KN; Matin SF
    J Urol; 2022 Oct; 208(4):886-895. PubMed ID: 36082549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
    Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
    JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
    Guntupalli SR; Brennecke A; Behbakht K; Tayebnejad A; Breed CA; Babayan LM; Cheng G; Ramzan AA; Wheeler LJ; Corr BR; Lefkowits C; Sheeder J; Matsuo K; Flink D
    JAMA Netw Open; 2020 Jun; 3(6):e207410. PubMed ID: 32589230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
    Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
    Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
    Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
    Huang J; Cao Y; Liao C; Wu L; Gao F
    Thromb Haemost; 2011 Feb; 105(2):245-53. PubMed ID: 20941455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
    King DA; Pow RE; Dickison DM; Vale PR
    Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
    N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
    Imberti D; Gallerani M; Manfredini R
    J Thromb Thrombolysis; 2012 Aug; 34(2):208-13. PubMed ID: 22466929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
    Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Hornick P;
    Lancet; 2010 Mar; 375(9717):807-15. PubMed ID: 20206776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
    Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
    J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery.
    Glickman A; Brennecke A; Tayebnejad A; Matsuo K; Guntupalli SR; Sheeder J
    Gynecol Oncol; 2020 Nov; 159(2):476-482. PubMed ID: 32854972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban or enoxaparin: Which is better for thromboprophylaxis after total hip and total knee arthroplasty in Indian patients?
    Kunal K; Banerjee S; Garg PK; Elhence A
    Br J Clin Pharmacol; 2022 Feb; 88(2):830-835. PubMed ID: 34184315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
    Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
    J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
    Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Portman RJ
    N Engl J Med; 2009 Aug; 361(6):594-604. PubMed ID: 19657123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
    Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT
    J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
    Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events after Radical Cystectomy Compared to Inpatient Only Subcutaneous Heparin.
    Pariser JJ; Pearce SM; Anderson BB; Packiam VT; Prachand VN; Smith ND; Steinberg GD
    J Urol; 2017 Feb; 197(2):302-307. PubMed ID: 27569434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.